Beyond Air Inc. Common Stock (XAIR)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-and-Buffett-style investor, I start with business quality and staying power. Beyond Air is a commercial-stage medical device company with LungFit PH for persistent pulmonary hypertension of the newborn and pipeline programs; it has only 54 employees and FY2026 revenue of $7.7 million (year ended 2026-03-31), up from $3.7 million in FY2025 and $1.2 million in FY2024. But FY2026 net income was -$33.2 million, versus -$46.6 million in FY2025 and -$60.2 million in FY2024, and in fiscal Q1 2027 (quarter ended 2026-06-30) revenue was $1.8 million with net income of -$7.9 million. That is not evidence of a durable moat; adoption is small and losses are enormous relative to sales. Financial health is poor: trailing free cash flow was -$19.6 million, FairStock's FCF yield was -359.6% at the 2026-10-26 close, debt/equity was 8.31, FairStock's Piotroski was 3/9, and FairStock's Altman Z was -13.86. The FairStock P/B of 0.80 at that close looks superficially cheap, but FairStock's P/E is negative at -0.04 and ROE/ROCE are deeply negative. FairStock score 63/100 and no Lynch category because of four loss years. At a $5.4 million market cap, I see speculative optionality, not a margin-of-safety bargain.

In plain English: Beyond Air is a small medical device company selling a treatment for newborns with persistent pulmonary hypertension and developing other lung and cancer therapies. The business is not yet strong: revenue is tiny and it has posted losses in each of the last four years, with heavy cash use. At $2.14 a share on 2026-10-26, the price looks low relative to accounting value, but the losses make it hard to call cheap with confidence.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-06-30) · fiscal Q3 2026 10-Q (period ended 2025-12-31) · fiscal Q2 2026 10-Q (period ended 2025-09-30) · fiscal Q1 2026 10-Q (period ended 2025-06-30) · FY2026 10-K (period ended 2026-03-31) · FY2025 10-K (period ended 2025-03-31) · FY2024 10-K (period ended 2024-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer